PURPOSE: Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer. METHODS: Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey). RESULTS: Men with prostate cancer who carried the minor 'T' allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare 'C' allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05). CONCLUSIONS: Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.
PURPOSE: Improved survival for men with prostate cancer has led to increased attention to factors influencing quality of life (QOL). As protein levels of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) have been reported to be associated with QOL in people with cancer, we sought to identify whether single-nucleotide polymorphisms (SNPs) of these genes were associated with QOL in men with prostate cancer. METHODS: Multiple linear regression of two data sets (including approximately 750 men newly diagnosed with prostate cancer and 550 men from the general population) was used to investigate SNPs of VEGF and IGF-1 (10 SNPs in total) for associations with QOL (measured by the SF-36v2 health survey). RESULTS:Men with prostate cancer who carried the minor 'T' allele for IGF-1 SNP rs35767 had higher mean Role-Physical scale scores (≥0.3 SD) compared to non-carriers (p < 0.05). While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer. Men from the general population who carried the rare 'C' allele had higher mean Bodily Pain scale scores (≥0.3 SD) than non-carriers (p < 0.05). CONCLUSIONS: Through identifying SNPs that are associated with QOL in men with prostate cancer and men from the general population, this study adds to the mapping of complex interrelationships that influence QOL and suggests a role for IGF-I in physical QOL outcomes. Future research may identify biomarkers associated with increased risk of poor QOL that could assist in the provision of pre-emptive support for those identified at risk.
Authors: James C Romeis; Andrew C Heath; Hong Xian; Seth A Eisen; Jeffery F Scherrer; Nancy L Pedersen; Qiang Fu; Kathleen K Bucholz; Jack Goldberg; Michael J Lyons; Brian Waterman; Ming T Tsuang; William R True Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Iona Cheng; Daniel O Stram; Kathryn L Penney; Malcolm Pike; Loïc Le Marchand; Laurence N Kolonel; Joel Hirschhorn; David Altshuler; Brian E Henderson; Matthew L Freedman Journal: J Natl Cancer Inst Date: 2006-01-18 Impact factor: 13.506
Authors: Peter D Baade; Joanne F Aitken; Megan Ferguson; Robert A Gardiner; Suzanne K Chambers Journal: BMC Cancer Date: 2010-08-23 Impact factor: 4.430
Authors: Christine Miaskowski; Bruce A Cooper; Michelle Melisko; Lee-May Chen; Judy Mastick; Claudia West; Steven M Paul; Laura B Dunn; Brian L Schmidt; Marilyn Hammer; Frances Cartwright; Fay Wright; Dale J Langford; Kathryn Lee; Bradley E Aouizerat Journal: Cancer Date: 2014-05-02 Impact factor: 6.860
Authors: Felicity Lose; Christina M Nagle; Tracy O'Mara; Jyotsna Batra; Kelly L Bolton; Honglin Song; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Mary-Anne Kedda; Amanda B Spurdle Journal: Gynecol Oncol Date: 2010-09-15 Impact factor: 5.482
Authors: Sofie De Langhe; Kim De Ruyck; Piet Ost; Valérie Fonteyne; Joke Werbrouck; Gert De Meerleer; Wilfried De Neve; Hubert Thierens Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-02 Impact factor: 7.038
Authors: Mirjam A G Sprangers; Jeff A Sloan; Andrea Barsevick; Cynthia Chauhan; Amylou C Dueck; Hein Raat; Quiling Shi; Cornelis J F Van Noorden Journal: Qual Life Res Date: 2010-10-14 Impact factor: 4.147
Authors: Christopher A Peters; Richard G Stock; Jamie A Cesaretti; David P Atencio; Sheila Peters; Ryan J Burri; Nelson N Stone; Harry Ostrer; Barry S Rosenstein Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-08 Impact factor: 7.038
Authors: Anne R Cotter; Kim Vuong; Linda Mustelin; Yi Yang; Malika Rakhmankulova; Colleen J Barclay; Russell P Harris Journal: BMJ Open Date: 2017-12-12 Impact factor: 2.692
Authors: Araba A Adjei; Camden L Lopez; Daniel J Schaid; Jeff A Sloan; Jennifer G Le-Rademacher; Charles L Loprinzi; Aaron D Norman; Janet E Olson; Fergus J Couch; Andreas S Beutler; Celine M Vachon; Kathryn J Ruddy Journal: Cancers (Basel) Date: 2021-02-10 Impact factor: 6.639